Prophase labs announces excellent progress with crown medical collections targeting over $50 million in net near-term cash recovery from covid-19 receivables

Company actively pursuing strategic alternatives including the potential sale of nebula genomics and dna complete to unlock immediate cash garden city, ny, feb. 20, 2025 (globe newswire) -- prophase labs, inc. (nasdaq: prph) ("prophase" or the "company"), a next-generation biotech, genomics, and consumer products company, is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of outstanding covid-19 receivables. these initiatives are expected to generate significant liquidity starting in the next few months and strengthen the company's balance sheet.
CCK Ratings Summary
CCK Quant Ranking